Price variability of TNF-α inhibitor biosimilars among European countries

Davide Geat*, Paolo Gisondi, Martina Maurelli, Luis Puig, Carle Paul, Diamant Thaçi, Lars Iversen, Francesco Bellinato, Giampiero Girolomoni

*Corresponding author for this work

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperComment/debate/letter to the editorResearchpeer-review

Original languageEnglish
JournalJournal of the European Academy of Dermatology and Venereology
Volume38
Issue8
Pages (from-to)e663-e665
ISSN0926-9959
DOIs
Publication statusPublished - Aug 2024

Keywords

  • Biosimilar Pharmaceuticals/economics
  • Europe
  • Humans
  • Tumor Necrosis Factor-alpha/antagonists & inhibitors
  • Infliximab/economics
  • Drug Costs
  • Adalimumab/therapeutic use

Cite this